Dec 3, 2018 Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Presentation at the 60th American Society of Hematology Annual Meeting & Exposition
Nov 29, 2018 Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer
Nov 26, 2018 Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer
Nov 12, 2018 Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update
Nov 9, 2018 Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus Infection
Nov 5, 2018 Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporate Highlights
Nov 1, 2018 Oncolytics Biotech® Announces Abstract for ASH Annual Meeting & Exposition Demonstrating Pelareorep Increases PD-L1 Expression When Combined with a Proteasome Inhibitor
Oct 22, 2018 Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018
